IMPROVEMENT OF STREPTOZOCIN-INDUCED T YPE I DIABETES MELLITUS PROTOCOL IN ADULT MALE WISTAR RATS
Keywords:Wistar rat, diabetes mellitus type I, diabetes mellitus model, streptozocin
Animal model of type 1 diabetes mellitus (T1DM) is a useful tool to test the efficacy of the modern medicines, study the course of surgical comorbidities and complications on the background of chronic hyperglycemia and pathology of the target organs. We aimed to improve streptozocin-induced T1DM protocol in adult male Wistar rats by combination of the approaches to decrease the toxic effect of the chemical agents, prevent hypoglycemia and, as a result, reduce the animal mortality rate. Adult male Wistar rats were divided into 2 groups: control — 20 animals and experimental — 20 animals. Protocol of steptozocin-induced T1DM (for both groups) consisted of the single intraperitoneal injection of the streptozocin solution (60 mg/kg). In order to prevent transitional hypoglycemia, animals (experimental group) were supplied with 10% Glucose solution or normal saline (control group) per os ad libitum for 24 h immediately after the injection. Glycaemia was measured by blood sugar monitor Accu Check (Roche, Germany). Blood sugar > 14 mmol/l was considered as the criterium of T1DM. Continuous monitoring of glycemia was used (48/96/168) to detect the risk of possible reversion. Hyperglycemia > 14 mmol/l was detected in 9% (19/20) of animals (experimental group) and 40% (8/20) control animals 48 h after induction; mortality rate was 5% and 55%, respectively. Reversion was identified in 2 rats of the experimental group 96 h after induction. Hence, improved T1DM induction protocol which included single intaperitoneal injection of the streptozocin solution (60 mg/kg), 12 h fasting period prior to the procedure and prevention of the transient hypoglycemia by administration of 10% glucose solution is an effective method to induce T1DM in adult male Wistar rats which induces clinically significant hyperglycemia (> 14 mmol/L). It is necessary to control blood glucose after T1DM confirmation in order to detect spontaneous reversion.
Patterson CC, Karuranga S, Salpea P, et al. Diab Res Clin Pract 2019; 157. https://doi.org/10.1016/j.diabres.2019.107842.
Qinna NA, Badwan AA. Drug design, development and therapy 2015; 9: 2515-2525. https://doi.org/10.2147/DDDT.S79885.
Mozhejko LA. Zhurn Grodnen gos med un-ta 2013; 4(44): 5-10, available at: http://elib.grsmu.by/handle/files/2350.
Kawano K, Hirishima T, Mori S, et al. Rat News Lett 1989; 22: 14-15.
Goyal SN, Reddy NM, Patil KR, et al. Chemico-Biological Interactions 2016; 244: 49-63. https://doi.org/10.1016/j.cbi.2015.11.032.
Stoenoiu MS, De Vriese AS, Brouet A, et al. Kidney Int 2002; 62(2): 668-678. https://doi.org/10.1046/j.1523-1755.2002.00487.x.
Duan X, Qin G. Mol Med Rep 2020; 21(2): 583-588. https://doi.org/10.3892/mmr.2019.10857.
Ramos-Lobo AM, Buonfiglio DC, Cipolla-Neto J. Diabetol Metab Syndr 2015; 7: 39. https://doi.org/10.1186/s13098-015-0035-2.
Szkudelski T. Exp Biol Med 2012; 237(5): 481-490. https://doi.org/10.1258/ebm.2012.011372.
Karan SK, Mondal A, Mishra SK. Pharm Biol 2013; 51(3): 369-375. https://doi.org/10.3109/13880209.2012.730531.
Saleh D, Bayoumi A, El-Eraky W, El-Khatib A. Bull Faculty Pharm, Cairo University 2013; 51. https://doi.org/10.1016/j.bfopcu.2013.03.002.
Akbarzadeh A, Norouzian D, Mehrabi MR, et al. Indian J Clin Biochem 2007; 22(2): 60-64. https://doi.org/10.1007/BF02913315.